Literature DB >> 18976802

Expression of membrane type 1 matrix metalloproteinase (MMP-14) in epithelial ovarian cancer: high level expression in clear cell carcinoma.

Brian P Adley1, Kara J Gleason, Ximing J Yang, M Sharon Stack.   

Abstract

OBJECTIVE: Clear cell carcinomas of the ovary constitute approximately 5% of all ovarian neoplasms and have a distinct gene expression profile relative to other ovarian carcinoma histotypes. Tumors often present as an early stage large pelvic mass with a high degree of recurrence and frequent early metastasis. Matrix metalloproteinases (MMPs) play a role in intraperitoneal metastasis through breakdown of cell-cell and cell-matrix barriers, enabling anchoring of secondary lesions and promoting proliferation in a geometrically constrained matrix environment. The objective of this study was to evaluate MMP expression in ovarian clear cell carcinoma.
METHODS: Immunohistochemistry was used to evaluate expression of membrane type 1 MMP (MMP-14), MMP-2 and MMP-9 in a panel of ovarian tumors. Western blotting and gelatin zymography were used to examine MMP-14 expression and activity in the clear cell carcinoma cell line ES2. The ability of ES2 cells to invade and proliferate within three-dimensional collagen gels was evaluated.
RESULTS: High level expression of MMP-14 and MMP-2 were observed in ovarian clear cell carcinoma relative to other histotypes (94-95% strong positive). MMP-14 was expressed and active in cultured ES2 cells. ES2 cells also exhibited MMP-dependent invasion of and proliferation within three-dimensional collagen gels.
CONCLUSIONS: The high level expression of MMP-14 together with in vitro functional analyses suggest that MMP-14 may contribute to both the proliferative capacity and the enhanced parenchymal metastasis of ovarian clear cell carcinoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18976802      PMCID: PMC2663392          DOI: 10.1016/j.ygyno.2008.09.025

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  41 in total

1.  Isolation, culture and characterization of human peritoneal mesothelial cells.

Authors:  E Stylianou; L A Jenner; M Davies; G A Coles; J D Williams
Journal:  Kidney Int       Date:  1990-06       Impact factor: 10.612

Review 2.  Membrane-type 1 matrix metalloproteinase: a key enzyme for tumor invasion.

Authors:  Motoharu Seiki
Journal:  Cancer Lett       Date:  2003-05-08       Impact factor: 8.679

3.  Increased expression of tissue inhibitor of metalloproteinase-2 in clear cell carcinoma of the ovary.

Authors:  Tomomitsu Okamoto; Rong Niu; Satoru Yamada
Journal:  Mol Hum Reprod       Date:  2003-10       Impact factor: 4.025

4.  Differential regulation of membrane type 1-matrix metalloproteinase activity by ERK 1/2- and p38 MAPK-modulated tissue inhibitor of metalloproteinases 2 expression controls transforming growth factor-beta1-induced pericellular collagenolysis.

Authors:  Hidayatullah G Munshi; Yi I Wu; Subhendu Mukhopadhyay; Adam J Ottaviano; Antonella Sassano; Jennifer E Koblinski; Leonidas C Platanias; M Sharon Stack
Journal:  J Biol Chem       Date:  2004-07-09       Impact factor: 5.157

5.  Functional role of matrix metalloproteinases in ovarian tumor cell plasticity.

Authors:  Anil K Sood; Mavis S Fletcher; Jeremy E Coffin; Maria Yang; Elisabeth A Seftor; Lynn M Gruman; David M Gershenson; Mary J C Hendrix
Journal:  Am J Obstet Gynecol       Date:  2004-04       Impact factor: 8.661

6.  Collagen binding properties of the membrane type-1 matrix metalloproteinase (MT1-MMP) hemopexin C domain. The ectodomain of the 44-kDa autocatalytic product of MT1-MMP inhibits cell invasion by disrupting native type I collagen cleavage.

Authors:  Eric M Tam; Yi I Wu; Georgina S Butler; M Sharon Stack; Christopher M Overall
Journal:  J Biol Chem       Date:  2002-07-26       Impact factor: 5.157

7.  Glycosylation broadens the substrate profile of membrane type 1 matrix metalloproteinase.

Authors:  Yi I Wu; Hidayatullah G Munshi; Ratna Sen; Scott J Snipas; Guy S Salvesen; Rafael Fridman; M Sharon Stack
Journal:  J Biol Chem       Date:  2003-12-11       Impact factor: 5.157

8.  Gene expression patterns in ovarian carcinomas.

Authors:  Marci E Schaner; Douglas T Ross; Giuseppe Ciaravino; Therese Sorlie; Olga Troyanskaya; Maximilian Diehn; Yan C Wang; George E Duran; Thomas L Sikic; Sandra Caldeira; Hanne Skomedal; I-Ping Tu; Tina Hernandez-Boussard; Steven W Johnson; Peter J O'Dwyer; Michael J Fero; Gunnar B Kristensen; Anne-Lise Borresen-Dale; Trevor Hastie; Robert Tibshirani; Matt van de Rijn; Nelson N Teng; Teri A Longacre; David Botstein; Patrick O Brown; Branimir I Sikic
Journal:  Mol Biol Cell       Date:  2003-09-05       Impact factor: 4.138

9.  Collagen production by human mesothelial cells in vitro.

Authors:  W Harvey; P L Amlot
Journal:  J Pathol       Date:  1983-03       Impact factor: 7.996

Review 10.  Clear cell adenocarcinoma of the ovary: a clinical analysis and comparison with serous carcinoma.

Authors:  E L Jenison; A G Montag; C T Griffiths; W R Welch; P T Lavin; J Greer; R C Knapp
Journal:  Gynecol Oncol       Date:  1989-01       Impact factor: 5.482

View more
  19 in total

Review 1.  Protein biomarkers of ovarian cancer: the forest and the trees.

Authors:  Brian M Nolen; Anna E Lokshin
Journal:  Future Oncol       Date:  2012-01       Impact factor: 3.404

2.  A role of MMP-14 in the regulation of invasiveness of nasopharyngeal carcinoma.

Authors:  Jian Zhao; Zhongyu Kong; Feng Xu; Wei Shen
Journal:  Tumour Biol       Date:  2015-06-04

3.  Proteolysis of EphA2 Converts It from a Tumor Suppressor to an Oncoprotein.

Authors:  Naohiko Koshikawa; Daisuke Hoshino; Hiroaki Taniguchi; Tomoko Minegishi; Taizo Tomari; Sung-Ouk Nam; Mikiko Aoki; Takayuki Sueta; Takashi Nakagawa; Shingo Miyamoto; Kazuki Nabeshima; Alissa M Weaver; Motoharu Seiki
Journal:  Cancer Res       Date:  2015-06-30       Impact factor: 12.701

Review 4.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

Authors:  Roopali Roy; Jiang Yang; Marsha A Moses
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

5.  Expressions of matrix metalloproteinase-7 and matrix metalloproteinase-14 associated with the activation of extracellular signal-regulated kinase1/2 in human brain gliomas of different pathological grades.

Authors:  Hui Xie; Yi-xue Xue; Li-bo Liu; Ping Wang; Yun-hui Liu; Hao-qiang Ying
Journal:  Med Oncol       Date:  2010-08-31       Impact factor: 3.064

6.  Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination.

Authors:  Natalie M Moss; Maria V Barbolina; Yueying Liu; Limin Sun; Hidayatullah G Munshi; M Sharon Stack
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

Review 7.  EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.

Authors:  Laurie G Hudson; Natalie M Moss; M Sharon Stack
Journal:  Future Oncol       Date:  2009-04       Impact factor: 3.404

8.  Epidermal growth factor receptor-mediated membrane type 1 matrix metalloproteinase endocytosis regulates the transition between invasive versus expansive growth of ovarian carcinoma cells in three-dimensional collagen.

Authors:  Natalie M Moss; Yueying Liu; Jeff J Johnson; Philip Debiase; Jonathan Jones; Laurie G Hudson; Hidayatullah G Munshi; M Sharon Stack
Journal:  Mol Cancer Res       Date:  2009-06-09       Impact factor: 5.852

9.  Transcriptome analysis reveals an unexpected role of a collagen tyrosine kinase receptor gene, Ddr2, as a regulator of ovarian function.

Authors:  Hirokazu Matsumura; Kiyoshi Kano; Caralina Marín de Evsikova; James A Young; Patsy M Nishina; Jürgen K Naggert; Kunihiko Naito
Journal:  Physiol Genomics       Date:  2009-08-11       Impact factor: 3.107

Review 10.  Screening, epidemiology, molecular biology, and treatment strategies for endometriosis-associated ovarian cancer.

Authors:  Hiroshi Kobayashi
Journal:  Reprod Med Biol       Date:  2009-09-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.